A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects

NCT06139367 | Unknown Phase 1

• 1 other identifier: TQB3454-I-03
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open, parallel, single center phase I clinical trial to evaluate the impact of food on the pharmacokinetics of TQB3454 tablets in healthy adult subjects. The aim is to evaluate the impact of food on the pharmacokinetics as well as the safety after single dose of TQB3454 tablets taken orally by Chinese healthy adult subjects, with pharmacokinetic indicators as the primary endpoint.

Conditions

Biliary Carcinoma

Keywords

Food effect

Outcome Measures

Primary Outcomes (10)

• Peak concentration (Cmax)

  Maximum plasma drug concentration

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Area under the time-concentration curve from 0 to t hours (AUC0-t)

  Area under the plasma concentration-time curve from the time of first dose to the time of the last measurable concentration.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Area under the time-concentration curve from 0 to infinity (AUC0-∞)

  Area under the plasma concentration-time curve from the time of first dose extrapolated to infinity

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Time to peak (Tmax)

  Time to reach maximum plasma concentration after drug administration

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Elimination half-life (t1/2)

  The time it takes for the blood concentration of a drug to decrease from its highest value to half in the body.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Apparent volume of distribution (Vd/F)

  The ratio of the amount of drug in the body to the concentration in the blood.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Apparent clearance (CL/F)

  Apparent total clearance of the drug from plasma after oral administration.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Elimination rate constant (λz)

  Terminal disposition rate constant/terminal rate constant

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Lag time (tlag)

  The time required from the start of administration to the appearance of the drug in the blood.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

• Percentage of residual area (AUC% Extrap)

  Residual area as a percentage of the entire area under curve.

  pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 264, 330 hours after dose.

Secondary Outcomes (2)

• Adverse event rate

  Before the first administration to 360 hours after the last administration.

• Adverse event severity

  Before the first administration to 360 hours after the last administration.

Study Arms (2)

TQB3454 tablets under fast condition

EXPERIMENTAL

TQB3454 tablets 600mg, take one dose orally under fast condition.

Drug: TQB3454 tablets

TQB3454 tablets under fed condition

EXPERIMENTAL

TQB3454 tablets 600mg, take one dose orally under fed condition.

Drug: TQB3454 tablets

Interventions

TQB3454 tablets DRUG

TQB3454 is a Isocitrate dehydrogenase 1 (IDH1) mutation inhibitor.

TQB3454 tablets under fast condition; TQB3454 tablets under fed condition

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Sign an informed consent form before the experiment and fully understand the content, process, and potential adverse reactions of the study;
• Able to complete the study according to the requirements of the protocol;
• Subjects aged 18-65 (inclusive);
• Body mass index (BMI) ≥ 18 and ≤ 28 kg/m\^2, and male's weight ≥ 50 kg and female's weight ≥ 45 kg;
• Health status: No mental abnormalities, no history of severe neurological, respiratory, digestive, urinary, endocrine, and metabolic abnormalities;
• The subjects have no pregnancy plan, voluntarily take effective contraceptive measures, and no plans to donate sperm or eggs, from the date of signing the inform consent (14 days before signing the inform consent for female subjects) to at least 6 months after the last administration.

You may not qualify if:

• Subjects with allergic constitution or a history of allergies to two or more foods or drugs;
• Subjects who have experienced arterial/venous thrombosis events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis, and pulmonary embolism;
• Suffering from ≥ Level 2 myocardial ischemia or infarction, arrhythmia (including QTc ≥ 450 ms for male, QTc ≥ 470 ms for female), and ≥ Level 2 congestive heart failure (New York Heart Association (NYHA) classification);
• Those with multiple factors that affect oral medication (such as inability to swallow, gastrointestinal diseases);
• Have taken any prescription, over-the-counter, vitamin product, or herbal medicine within one month before the first administration;
• Take CYP3A4 inhibitors or inducers within one month before the first administration or before the study medication;
• Those who have taken a special diet (including grapefruit, etc.) or engaged in vigorous exercise within 14 days before the first administration or have other factors that affect drug absorption, distribution, metabolism, excretion, etc.;
• Abnormal and clinically significant physical examination, vital signs, electrocardiogram, and laboratory tests during the screening period;
• Donated blood or experienced significant blood loss (\>450 mL) within 3 months prior to taking the study drug;
• Participated in any clinical trial and took any investigational drug within 3 months prior to taking the study drug;
• Smoke at least 5 cigarettes per day within 3 months prior to the study;
• Positive alcohol breath test or history of alcoholism within 2 weeks prior to screening (drinking 14 units of alcohol per week: 1 unit=360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine);
• Drug screening positive or those who have used drugs in the past 3 months prior to the study;
• Inability to tolerate venous puncture for blood collection or poor vascular condition;
• The subject is unable to complete the experiment due to personal reasons;

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 400010, China

Location

Central Study Contacts

Yu Cao, Master of Medicine

CONTACT

18661809090; caoyu1767@126.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 15, 2023
• First Posted: November 18, 2023
• Study Start: November 1, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: November 18, 2023

Record last verified: 2023-11

Locations

CN (1)